Key facts
- PierianDx’s last known valuation is $133.0M (Aug 2020).
- It has raised $116.0M across 3 recorded rounds; the latest was Early Stage VC ($17.0M) in Jun 2021.
- Notable investors include Washington University in St. Louis, Frazier VC.
- PierianDx has filed 3 Form Ds with the SEC since 2018, most recently Nov 2021 ($17.0M sold to 13 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for PierianDx
Funding rounds
3 roundsAbout PierianDx
Developer of a cloud-based clinical software designed to facilitate research on the sequencing testing process. The company's software uses artificial intelligence to automate the process of taking DNA sequencing data through analysis, interpretation and final report, thereby empowering physicians in the laboratory and clinic to effectively diagnose and treat patients with cancer and other complex diseases.
- Sector
- Healthcare
- HQ
- Creve Coeur, MO, United States
- Founded
- 2014
- Employees
- 320
- Website
- pieriandx.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
PierianDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PierianDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PierianDx in its N-PORT filings yet. We sweep new filings monthly.